dr. chachoua on afatinib for exon 19 mutation in lung cancer
Published 9 years ago • 569 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
16:22
debate: drug of choice for exon 19 del egfr mutant nsclc - afatinib
-
4:09
frontline afatinib in egfr-mutant nsclc
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
1:25
dr. bunn discusses afatinib in lung cancer
-
8:38
afatinib plus cetuximab in resistant non-small cell lung cancer
-
1:11
dr. gitlitz on egfr exon 20 insertion mutations in lung cancer
-
4:06
afatinib in patients with uncommon egfr mutations
-
3:07
efficacy and safety of afatinib vs erlotinib and gefitinib in egfr nsclc
-
3:29
burden of egfr exon 20 mutation in nsclc
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
1:35
dr. bunn discusses afatinib for patients with egfr mutation
-
1:30
dr. langer on afatinib for advanced non-small cell lung cancer
-
0:45
dr. corey langer discusses afatinib in egfr-positive nsclc
-
1:25
dr. giorgio scagliotti discusses afatinib in patients with egfr mutation
-
8:20
tkis for egfr del19 and beyond progression
-
8:47
study of 693 nsclc patients treated with afatinib
-
1:19
dr. chaft on predictive biomarkers in lung cancer
-
1:35
dr. janjigian discusses afatinib and cetuximab for patients with egfr-mutant lung cancer